Search

Displaying results 6231 - 6240 of 10000 in total
  1. Drug

    Salix lucida ssp. lasiandra pollen

    go.drugbank.com/drugs/DB10916
    Approved

    Salix lucida ssp. lasiandra pollen is mainly used in allergenic testing.

  2. Drug

    Sorghum bicolor subsp. bicolor pollen

    go.drugbank.com/drugs/DB10965
    Approved

    Sorghum bicolor subsp. bicolor pollen is mainly used in allergenic testing.

  3. Drug

    Sorghum bicolor subsp. drummondii pollen

    go.drugbank.com/drugs/DB10966
    Approved

    Sorghum bicolor subsp. drummondii pollen is mainly used in allergenic testing.

  4. Drug

    Proxibarbal

    go.drugbank.com/drugs/DB13253
    Approved

    Proxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia [L5476].

  5. Drug

    Rocapuldencel-T

    go.drugbank.com/drugs/DB17588
    Investigational

    Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

  6. Drug

    Amedalin

    go.drugbank.com/drugs/DB09188
    Experimental

    Amedalin is a selective norepinephrine reuptake inhibitor developed in the 1970s. … It has no significant effect on reuptake of serotonin and dopamine and no antihistamine or anticholinergic properties. This drug was never marketed.

  7. Drug

    Talbutal

    go.drugbank.com/drugs/DB00306
    ApprovedIllicit

    Talbutal is a schedule III drug in the U.S.

  8. Drug

    JPC-3210

    go.drugbank.com/drugs/DB15609
    Experimental

    It is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant _Plasmodium falciparum_ lines, low cytotoxicity, potent in vivo efficacy against murine malaria

  9. Drug

    Furvina

    go.drugbank.com/drugs/DB16547
    Experimental

    Furvina is marketed in Cuba as Dermofural®, an ointment containing G1 as the only active principle ingredient. It is used to treat dermatological infections.[A228063] … Furvina (G1) is an antimicrobial agent active against Gram-positive and Gram-negative bacteria, yeasts, and filamentous fungi.

  10. Drug

    EpiVacCorona

    go.drugbank.com/drugs/DB16439
    Investigational

    EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus[L30608]. … It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575)[L30608, L30613].